Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Epitranscriptomic Therapies Market Poised To Hit $4.2 Billion By 2030 With A 21.9% CAGR
The epitranscriptomic therapies market has experienced rapid expansion in its size over the past few years. This market is projected to expand from $1.56 billion in 2025 to $1.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 21.6%. Historically, this expansion has been driven by several factors, including developments in RNA biology research, an enhanced comprehension of gene regulation mechanisms, the proliferation of oncology research initiatives, the accessibility of sophisticated sequencing technologies, and a rise in translational medicine endeavors.
The epitranscriptomic therapies market is anticipated to show significant expansion over the next few years, projected to reach $4.2 billion in 2030, with a compound annual growth rate (CAGR) of 21.9%. This projected growth within the forecast timeframe stems from increased investments in RNA-based therapeutics, a rising demand for targeted cancer treatments, the broadening of personalized medicine approaches, heightened clinical trial activity in epitranscriptomics, and growing regulatory engagement for novel RNA therapies. Prominent trends for the forecast period encompass the increasing development of epitranscriptomic drug pipelines, the growing utilization of RNA modification profiling tools, an expansion of combination epitranscriptomic therapies, the rising integration of bioinformatics in therapy design, and an enhanced focus on precision medicine applications.
Get A Free Sample Report With In-Depth Market Insights:
Epitranscriptomic Therapies Market Industry Drivers: What’s Behind The Revenue Growth?
The escalating need for personalized medicine is anticipated to stimulate the expansion of the epitranscriptomic therapies market moving forward. Personalized medicine defines a healthcare approach that tailors medical decisions, treatments, and interventions to the unique characteristics of each patient, encompassing their genetic profile, lifestyle, and environment. This heightened demand for personalized medicine largely stems from the growing incidence of chronic and complex diseases, as customized treatments can more effectively address individual patient requirements and enhance outcomes. Personalized medicine aids epitranscriptomic therapies by adapting treatments to a person’s specific RNA modification patterns, thereby boosting therapeutic efficacy while simultaneously lowering the risk of adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. The personalized treatments newly approved for 2023 also included seven cancer drugs and three for other diseases and conditions. Consequently, the expanding demand for personalized medicine is fueling the growth of the epitranscriptomic therapies market.
Epitranscriptomic Therapies Market Segment Analysis Spotlighting Growth Areas
The epitranscriptomic therapies market covered in this report is segmented –
1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) By Route of Administration: Injectable; Oral; Other Routes Of Administration
3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors
2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes
3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides
4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies
#Epitranscriptomic Therapies Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the epitranscriptomic therapies market are increasingly focusing on forming strategic partnerships to develop innovative RNA-modifying treatments for cancer. These cooperative arrangements involve organizations combining their resources, knowledge, or strengths to pursue shared objectives, which in turn drives faster growth, reduces operational risks, and enhances market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, collaborated with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies targeting epitranscriptomic mechanisms. This collaboration is designed to integrate AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials of STC-15, which is a first-in-class METTL3 inhibitor. The partnership aims to identify and validate m6A RNA modification biomarkers that can predict patient responses and optimize therapeutic strategies. This joint effort combines drug development with advanced RNA profiling, representing a significant advancement in epitranscriptomic cancer therapies.
Epitranscriptomic Therapies Market Key Participants And Competitive Landscape
Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.
View The Full Epitranscriptomic Therapies Market Report:
Epitranscriptomic Therapies Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
